Objective To investigate the efficacy of Qishenhuanwu capsule in treatment of Parkinson′s disease (PD) patients with Qi and Blood Deficiency and its effect on Unified Parkinson′s disease rating scale (UPDRS) scores and balance ability. Methods A total of 130 PD patients with Qi and Blood Deficiency treated in our hospital from March 2018 to December 2019 were recruited in this study, and were divided into control group (n=65, simple Basizide tablet) and Qishenhuanwu treatment group (n=65, Qishenhuanwu capsule plus Basizide tablet). All of the patients were treated for 3 months. The treatment efficiency, traditional Chinese medicine (TCM) symptom score, UPDRS score, Berg Balance Scale score, the Parkinson′s disease questionnaire-39 score, and adverse reactions were compared before and after treatment between 2 groups. SPSS statistics 23.0 was used for statistical analysis. Data comparison between two groups was perfomed using t test or χ² test depending on data type. Results In 3 months after treatment, the total effective rate was 92.31% (60/65) in the Qishenhuanwu treatment group, significantly higher than that of the control group [80.00% (52/65), P<0.05]. After treatment, the TCM symptom score, UPDRSⅡ score, UPDRSⅢ score, and PDQ-36 score were all decreased, and the BBS score were increased in both groups (all P<0.05). The Qishenhuanwu group obtained better TCM symptom score, UPDRSⅡ score, and UPDRSⅢ score than the control group (all P＜0.05). The adverse reaction rate was 3.08% (2/65) in the Qishenhuanwu group and 7.69% (5/65) in the control group, but there was no statistical difference between them (P>0.05). Conclusion Qishenhuanwu capsule shows significant effectiveness in treatment of PD patients with Qi and Blood Deficiency, with less adverse reactions, and can improve daily activities, motor function, balance function and the life quality of the patients.